BRAF and melanoma: BRAF tyrosine kinase inhibitors (TKIs) have been successfully used in people with cutaneous melanoma, but due to the low frequency of BRAF mutation in mucosal melanoma, TKIs are rarely effective in this type of melanoma [92].